Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
Foster City, Calif. and Mechelen, Belgium; 23 August 2019; 22.01 CET; regulated information – Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on 14 July 2019.
This agreement has received clearance from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and merger control approval from the Austrian Federal Competition Authority.
Under the terms of the agreement, the closing of this transaction triggers an upfront license fee payment of $3.95 billion by Gilead to Galapagos. In addition, Gilead has made an equity investment in Galapagos of approximately $1.1 billion (or approximately €960 million) by subscribing for new shares at a price of €140.59 per share, including issuance premium. As a result, Gilead now owns 13,589,686 ordinary shares of Galapagos, representing approximately 22 percent of the currently outstanding share capital of Galapagos.
“We are excited to close this unique agreement, which will generate both long-term strategic value and mutual, immediate benefits,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead. “The collaboration reflects Gilead’s intent to grow our innovation network through diverse and creative partnerships.”
“This agreement is about maximizing innovation based on developing new mode of action medicines. With the capital provided by Gilead, we aim to progress innovation to patients,” said Onno van de Stolpe, Chief Executive Officer of Galapagos.
In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €333,479,569.76; the total number of securities conferring voting rights is 61,652,086, which is also the total number of voting rights (the “denominator”), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 5,958,292, which equals the total number of voting rights that may result from the exercise of these warrants. Galapagos does not have any convertible bonds or shares without voting rights outstanding.
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. The company’s pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Galapagos’ ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
Elizabeth Goodwin Carmen Vroonen
VP IR Senior Director Communications
+1 781 460 1784 +32 473 824 874
Sofie Van Gijsel Evelyn Fox
Director IR Director Communications
+32 485 19 14 15 +31 6 53 591 999
Sung Lee Amy Flood
+1 (650) 524-7792 +1 (650) 522-5643
Galapagos Forward-Looking Statements
This release may contain forward-looking statements with respect to Galapagos, including statements regarding Galapagos’ strategic ambitions, the implementation of the global collaboration agreement, and the amount and timing of any payments by Gilead to Galapagos. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos’ results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of its candidate products due to safety, efficacy or other reasons), Galapagos’ reliance on collaborations with third parties (including its collaboration partner Gilead), and estimating the commercial potential of its candidate products. A further list and description of these risks, uncertainties and other risks can be found in Galapagos’ Securities and Exchange Commission (SEC) filings and reports, including in Galapagos’ most recent annual report on Form 20-F filed with the SEC and subsequent filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
Gilead Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Galapagos and the global research and development collaboration agreement that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of the companies and members of their senior management team. Forward-looking statements include, without limitation, the risk that Gilead may not realize any benefits from the global collaboration agreement; its potential effects on Gilead’s revenues and earnings; Gilead may fail to discover, develop and commercialize any of Galapagos’ pipeline products under the agreement; the filing of the new drug applications for approval of filgotinib in the currently anticipated timeframe; approval of filgotinib by regulatory authorities, including any approvals, if granted, may have significant limitations on its use; the anticipated timing of clinical data of Galapagos’ pipeline products; the possibility of unfavorable results from these clinical trials; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: the occurrence of any event, change or other circumstance that could give rise to the termination of the collaboration agreement; the effects of the transaction on relationships with employees, customers, other business partners or governmental entities; transaction costs; the risk Galapagos’ stockholders do not approve Gilead’s board nominees or issuance of the warrants, as the case may be. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Result of Riksbank´s purchases of Commercial Paper27.5.2020 10:00:00 CEST | Press release
Auction date200527Requested volume, SEK mln4,000 Credit rating class1Term3MRequested volume, SEK mln1,000 +/-Fixed purchase rate0.55 %Total bid amount, SEK mln150 MioPrel. accepted volume, SEK mln150 MioPercentage alloted100.00 %Number of bids1 Credit rating class1Term6MRequested volume, SEK mln1,000 +/-Fixed purchase rate0.65 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage alloted100.00 %Number of bids0 Credit rating class2Term3MRequested volume, SEK mln1,000 +/-Fixed purchase rate0.85 %Total bid amount, SEK mln375 MioPrel. accepted volume, SEK mln375 MioPercentage alloted100.00 %Number of bids2 Credit rating class2Term6MRequested volume, SEK mln1,000 +/-Fixed purchase rate0.95 %Total bid amount, SEK mln250 MioPrel. accepted volume, SEK mln250 MioPercentage alloted100.00 %Number of bids2
Adevinta Ventures invests in MEDWING’s €28 million Series B funding round27.5.2020 09:09:17 CEST | Press release
Oslo, 26 May 2020 - Adevinta, through its Adevinta Ventures team, is investing for a second time in MEDWING, one of Europe’s leading healthtech companies, in a €28 million Series B funding round, led by Cathay Innovation, with participation from historical investors Northzone, Atlantic Labs and Cherry Ventures. This follows on from Adevinta’s first investment from December 2018. Founded in 2017 and based in Berlin, MEDWING aspires to make working in the healthcare sector more attractive and to solve the shortage of healthcare personnel. The company empowers candidates to work in a flexible way to suit their lifestyle and supports hospitals. They help with the recruitment process and human resources management by applying innovative matching, communication technology and personal consultations. Ovidiu Solomonov, VP Global Markets and Ventures at Adevinta, says: “Medwing gives power, autonomy and transparency to nurses, addressing some of the inefficiencies in the healthcare staffing ind
Notice to attend Elanders’ Annual General Meeting 202027.5.2020 09:00:00 CEST | Press release
Shareholders in Elanders AB (publ) are invited to attend the Annual General Meeting on Thursday 25 June 2020 at 10 a.m. at Södra Porten, Flöjelbergsgatan 1 C, Mölndal, Sweden. INFORMATION IN RELATION TO COVID-19 (CORONAVIRUS) In view of the ongoing spreading of the coronavirus, a number of precautionary measures are being taken in connection with the Annual General Meeting to reduce the risk for the shareholders and other persons attending the Meeting: Registration will not begin until 09.30 a.m.No food or drinks will be served. No gifts will be handed out.The address by the President will be kept very short.With a few exceptions, the Board of Directors and senior executives will not be present at the meeting room.Questions at the meeting will be concentrated on the decision points on the agenda and other information that the participants are entitled to receive according to law.The number of people attending who are not shareholders will be limited. Shareholders are therefore requeste
Kallelse till Elanders årsstämma 202027.5.2020 09:00:00 CEST | Pressemelding
Aktieägarna i Elanders AB (publ) kallas till årsstämma torsdagen den 25 juni 2020, kl. 10.00 på Södra Porten, Flöjelbergsgatan 1 C, Mölndal. INFORMATION MED ANLEDNING AV COVID-19 (CORONAVIRUSET) Mot bakgrund av den pågående smittspridningen av coronaviruset kommer ett antal säkerhetsåtgärder att vidtas i samband med årsstämman för att minska risken för aktieägare och andra som deltar vid stämman: Inregistreringen kommer inte att påbörjas förrän kl. 09.30.Ingen mat eller dryck kommer att serveras och inga gåvor kommer att delas ut.Anförandet av verkställande direktören kommer att hållas mycket kort.Styrelsen och bolagsledningen kommer, med några få undantag, inte närvara i stämmolokalen.Frågor på stämman kommer att koncentreras till beslutspunkterna på dagordningen och andra upplysningar som deltagarna har rätt att erhålla enligt lag.Antalet deltagare som inte är aktieägare kommer att begränsas. Aktieägare ombeds därför också att, om möjligt, avstå från att ta med biträden.Aktieägare up
Electra Gruppen kallar till Årsstämma27.5.2020 08:30:00 CEST | Pressemelding
ELECTRA GRUPPEN AB (publ) orgnr. 556065-4054 Pressmeddelande 2020-05-27 Electra Gruppen kallar till Årsstämma Electra Gruppen kallar till årsstämma. Stämman äger rum den 25 juni kl. 11.00 i Electras lokaler på Trångsundsvägen 20 i Kalmar. Kallelse till stämman återfinns på bolagets hemsida, www.electra.se samt är även publicerad i Post- och Inrikes tidningar. På hemsidan återfinns även material som ska finnas tillgängligt för aktieägare och intressenter samt fullmaktsunderlag. Som en konsekvens av Covid-19 pandemin önskar vi genomföra bolagstämman med så få fysiskt närvarande personer som möjligt. Aktieägare kommer beredas möjlighet att utöva sina rättigheter som aktieägare på annat sätt via deltagande digitalt på distans eller liknande upplägg. Information om detta kommer meddelas via bolagets hemsida senast 1 vecka innan stämmans genomförande. I kallelsen framgår att styrelsen föreslår stämman att ingen utdelning lämnas. Styrelsen kommunicerar att trots att Bolagets resultatutvecklin
CEO review at Cargotec's Annual General Meeting27.5.2020 08:15:00 CEST | Press release
CEO review at Cargotec's Annual General Meeting CARGOTEC CORPORATION, PRESS RELEASE, 27 MAY 2020 AT 9:15 AM (EEST) Cargotec Corporation's Annual General Meeting will be held today, 27 May 2020, at 1.00 p.m. Finnish time in Helsinki, Finland. The CEO review will focus on Cargotec’s financial results in 2019, company performance during the first quarter of 2020, and Cargotec’s climate ambition. The CEO review does not include any material new information. The presentation material is attached to this press release and is also available at www.cargotec.com. A video recording of the CEO review is available at Cargotec's website within coming days. Cargotec’s interim report January–March 2020 is available via this link. For further information, please contact: Hanna-Maria Heikkinen, Vice President, Investor Relations, tel. +358 20 777 4084, firstname.lastname@example.org Cargotec (Nasdaq Helsinki: CGCBV) enables smarter cargo flow for a better everyday with its leading cargo handling so